Feature | May 16, 2013

Zinc Bioresorbable Stents May Offer Alternative to Permanent Stents

Is Zinc the Goldilocks metal for bioabsorbable stents?

bioresorbable stent, zinc stent

A prototype bioresorbable zinc stent developed by the University of Michigan.

bioresorbable stent, zinc stent

Images showing the progression of stent strut bioresorption over several months.

May 15, 2013 — In 2012, more than 3 million people had stents inserted in their coronary arteries. After about six months, most damaged arteries are healed and stay open on their own. The stent, however, is there for a lifetime, which can cause negative side effects, leading to the development of bioresorbable stents.

Most of the time a conventional stent is not a problem, says Patrick Bowen, a doctoral student studying materials science and engineering at Michigan Technological University. The arterial wall heals in around the old stent with no ill effect. But the longer a stent is in the body, the greater the risk of late-stage side effects. For example, a permanent stent can cause intermittent inflammation and clotting at the implant site. In a small percentage of cases, the tiny metal segments that make up the stent can break and end up poking the arterial wall.

“When the stent stays in place 15, 20 or 25 years, you can see these side effects,” said Bowen. “It’s not uncommon to have a stent put in at age 60, and if you live to be 80, that’s a long time for something to remain inert in your body.”

That’s why researchers are trying to develop a bioabsorbable stent, one that would gradually — and harmlessly — dissolve after the blood vessel is healed.

Many studies have investigated iron- and magnesium-based stents. However, iron is not promising: it rusts in the artery. Magnesium, on the other hand, dissolves too quickly. “We wondered, ‘Isn’t there something else?’” Bowen said. “And we thought, ‘Why not zinc?’”

So they placed tiny zinc wires in the arteries of rats. The researchers said the results were amazing. “The corrosion rate was exactly where it needed to be,” Bowen said. The wires degraded at a rate just below 0.2 millimeters per year — the “magic” value for bioabsorbable stents — for the first three months. After that, the corrosion accelerated, so the implant would not remain in the artery for too long. On top of that, the rats’ arteries appeared healthy when the wires were removed, with tissue firmly grasping the implant.

“Plus, zinc reduces atherosclerosis,” he added, referring to zinc’s well-known ability to fight the development of plaque in the arteries. “How cool is that? A zinc stent might actually have health benefits.”

However, researchers said there is one drawback. “A stent made of conventional zinc would not be strong enough to hold open a human artery,” he said. “We need to beef it up, double the strength.”

“The good news is that there are commercial zinc alloys that are up to three times stronger,” Bowen said. “We know we can get there. We just don’t want to ruin our corrosion behavior.”

The researchers have filed a provisional patent on their discoveries and are now testing new zinc-based stent materials.

An article on their work, “Zinc Exhibits Ideal Physiological Corrosion Behavior for Bioabsorbable Stents,” was recently published May 14 in the journal Advanced Materials.

Bowen’s research is supported by a two-year, $52,000 predoctoral fellowship from the American Heart Association. Initial research was supported by a summer fellowship from the DeVlieg Foundation. Bowen’s advisor is Jaroslaw Drelich, a professor of materials science and engineering, and they work in close collaboration with Jeremy Goldman, an associate professor of biomedical engineering.

For more information: www.mtu.edu/news/


Related Content

Synergy stent
Technology | October 05, 2015
October 5, 2015 — The U.S.
News | Heart Failure| October 02, 2015
Cyberonics Inc. announced results from the extension of the ANTHEM-HF clinical study (ENCORE Study). Results of the...
Tryton Side Branch Stent, clinical trial results, Catheterization and Cardiovascular Interventions

Tryton Side Branch Stent image courtesy of Tryton Medical

News | Stents Bifurcation| October 02, 2015
October 2, 2015 — Tryton Medical Inc.
Intact Vascular, TOBA II study, Tack Endovascular System

Image courtesy of Intact Vascular

News | Peripheral Arterial Disease (PAD)| October 01, 2015
Intact Vascular Inc. announced the U.S. Food and Drug Administration has granted conditional approval for a U.S. and...
Johns Hopkins, sticky gel, stem cells, rat hearts, heart attacks

Hydrogel applied to beating rat hearts improves stem cell uptake by the heart muscle and speeds up tissue healing after heart attack. Image courtesy of Johns Hopkins Medicine.

News | Stem Cell Therapies| September 29, 2015
A sticky, protein-rich gel created by Johns Hopkins researchers appears to help stem cells stay on or in rat hearts and...
News | Cath Lab| September 29, 2015
The Innovation Institute announced that Boston Scientific has signed an agreement to become the founding medical device...
Eluvia drug-eluting vascular stent system, 12-month primary patency, Boston Scientific, MAJESTIC trial, CIRSE

Image courtesy of Boston Scientific

News | Stents Peripheral| September 28, 2015
New 12-month clinical trial outcomes assessing the safety and performance of the Boston Scientific Eluvia drug-eluting...
predicting arrhythmias, mcgill university, alternans patterns
News | EP Lab| September 28, 2015
Researchers have discovered how to predict some cardiac arrhythmias several steps before they even occur. It’s a...
News | Antiplatelet and Anticoagulation Therapies| September 25, 2015
The Icahn School of Medicine at Mount Sinai has launched the international TWILIGHT clinical trial to test the safety...
Medisafe, medication management, mHealth platform, blood pressure study, hypertension, adherence
News | Hypertension| September 25, 2015
Medisafe, an mHealth platform for medication management, announced the results of its blood pressure study, which...
Overlay Init